Angiotensin II Receptor Blocker
Candesartan for High Blood Pressure in Obesity
This trial will use chemicals and a drug called Candesartan to study how they affect certain receptors related to blood pressure. It focuses on obese individuals who often have high levels of a substance called ET-1, which is linked to high blood pressure. By blocking these receptors, the study aims to see if it can improve their function and help lower blood pressure in obese people. Candesartan has been studied extensively for its effects on blood pressure, particularly in hypertensive and obese patients.
Behavioral Intervention
ENACTS Intervention for High Blood Pressure
This trial will compare the effects of the ENACTS intervention on blood pressure and related outcomes to a control group. The intervention will also be evaluated for its ability to influence grocery store policy on clearly identifying low sodium or high potassium foods.
Behavioural Intervention
Medication Optimization Intervention for HIV/AIDS
This trial will compare the health outcomes of two groups of African-Americans with HIV who either receive medication optimization with access to their medical records or usual care without access to records.
Popular Filters
View More Related Trials
Frequently Asked Questions
Introduction to hypertension
What are the top hospitals conducting hypertension research?
When it comes to leading the charge in clinical trials for hypertension, several hospitals are making significant strides. In Boston, Massachusetts General Hospital has emerged as a pioneer with four ongoing trials dedicated to studying this condition. With an impressive history of 57 completed hypertension trials since embarking on their first investigation in 2002, this esteemed institution is at the forefront of cardiovascular research. Similarly, Brigham and Women's Hospital also situated in Boston is actively involved in three current hypertension trials while boasting a remarkable record of 82 previous studies dating back to their initial trial in 1999.
Moving south to Durham, North carolina, Duke University Medical Center stands strong alongside Massachusetts General Hospital with four active hypertension trials that contribute towards their extensive portfolio of 76 completed investigations since beginning their journey into understanding high blood pressure causes and treatments from as early as2003.The University of Pennsylvania located Philadelphia diligently conducts research through three ongoing hypertension clinical trials while having conducted fifty-four prior tests after recording its inaugural study focusing on hypertensive conditions way back until2005
Last but not least Piedmont Heart Institute located Atlanta may have a smaller number of ongoing investigations compared to other institutions; however they play an equally essential role by conducting three active clinical studies surrounding hypertension treatment options and prevention strategies.With only seven previously held experiments recorded since initiating such endeavors ten years ago-2011
These top hospitals showcase unwavering commitment and dedication towards combating one of the most prevalent health concerns worldwide—hypertension. Through these breakthroughs made possible by pioneering researchers across different locations notable advancements continue being made towards better understanding underlying mechanisms behind high blood pressure,and developing more effective preventative measures or innovative treatments ultimately benefitting millions affected by this condition around the globe
Which are the best cities for hypertension clinical trials?
When it comes to hypertension clinical trials, several cities emerge as key hubs for research. New york, with its 12 active trials, explores treatment options like the Symplicity Spyralâ„¢ multi-electrode renal denervation system and sleep hygiene/extension interventions. Boston follows closely behind with 11 ongoing studies focusing on innovative approaches such as Ralinepag and Vitamin d + fish oil. Additionally, Chicago and Philadelphia both have 9 active trials investigating promising treatments like CIN-107 and Amlodipine besylate. Lastly, Dallas also joins the ranks with 9 active trials studying interventions such as the Symplicity Spyralâ„¢ multi-electrode renal denervation system. These cities offer individuals living with hypertension access to cutting-edge clinical trials that pave the way for advancements in care and improved outcomes.
Which are the top treatments for hypertension being explored in clinical trials?
Hypertension research continues to advance, with several promising treatments being explored in clinical trials. Among the top contenders are:
- Community Health Navigator Program: Currently involved in two active trials and a total of three hypertension trials since its introduction in 2021.
- Angiotensin-(1-7): Showing great potential, this treatment is being tested in two ongoing trials and has been listed in a total of two hypertension studies since 2016.
- Intervention: With proven efficacy, this treatment is being evaluated in two current trials while having participated in six overall hypertension studies since 2014.
- Symplicity Spyralâ„¢ multi-electrode renal denervation system: Also vying for success, this treatment is currently under investigation in two active clinical trials and has been part of two previous hypertension studies since its initial listing back in 2015.
As researchers delve deeper into these innovative approaches, hope grows for the development of more effective interventions against hypertension.
What are the most recent clinical trials for hypertension?
Recent clinical trials in the field of hypertension have brought forth promising advancements for patients seeking effective treatment options. One such trial focused on inhibiting endoplasmic reticulum stress, a mechanism implicated in the development of hypertension. This approach underwent rigorous testing through both Phase 1 and Phase 2 studies, with results becoming available as of August 15, 2023. Another noteworthy trial investigated the effectiveness of Dose 2 in managing hypertension and reached Phase 2 by March 13, 2023. Additionally, a study explored the benefits of combining angiotensin II receptor blockers (ARBs) like losartan and calcium channel blockers (CCBs) such as amlodipine to tackle high blood pressure levels—an intervention that entered Phase 2 on October 25, 2022. With these recent developments marking significant progress in hypertensive research and care delivery approaches, patients can anticipate improved outcomes moving forward.
What hypertension clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of hypertension research. In April 2022, Ionis Pharmaceuticals successfully completed a trial evaluating ION904 as a potential treatment option. CinCor Pharma also achieved an important milestone in December 2021 with their completion of a trial investigating CIN-107. Furthermore, Columbia University concluded a study on Furosemide in October 2021, while Pfizer wrapped up their Prazosin HCl 2mg trial in September of the same year. These and other groundbreaking trials underline the ongoing efforts to advance our understanding and management of hypertension for the benefit of patients worldwide.